CRISPR Therapeutics Q2 2024 Adj EPS $(1.49) Beats $(1.52) Estimate, Sales $517.00K May Not Compare To $3.54M Estimate
Portfolio Pulse from Benzinga Newsdesk
CRISPR Therapeutics (NASDAQ:CRSP) reported Q2 2024 adjusted EPS of $(1.49), beating the estimate of $(1.52). However, sales were $517K, significantly missing the $3.54M estimate and representing a 99.26% decrease from the same period last year.
August 05, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CRISPR Therapeutics reported Q2 2024 adjusted EPS of $(1.49), beating the estimate of $(1.52). However, sales were $517K, significantly missing the $3.54M estimate and representing a 99.26% decrease from the same period last year.
While CRISPR Therapeutics managed to beat EPS estimates, the significant miss on sales and the drastic year-over-year decline in revenue are likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100